175968-15-7

Upstream product

• 82380-18-5 2-fluoro-4-hydroxybenzonitrile 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1221235-46-6 cyclopropyl(2-fluoro-4-hydroxyphenyl)methanone 
• 1221235-53-5 cyclobutyl(2-fluoro-4-hydroxyphenyl)methanone 
• 1221178-59-1 1-(2-fluoro-4-hydroxyphenyl)propan-1-one 
• 1208078-35-6 1-(2-fluoro-4-hydroxyphenyl)-2-methylpropan-1-one 
• 1221178-65-9 (R)-tert-butyl 6-(2-(tert-butoxycarbonyl(2-(3-(N-(tert-butoxycarbonyl)(methyl)sulfonamido)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-3-ethylindazole-1-carboxylate 
• 1221178-58-0 (R)-tert-butyl 6-(2-(tert-butoxycarbonyl-(2-(3-(N-(tert-butoxycarbonyl)(methyl)sulfonamido)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-3-isopropylindazole-1-carboxylate 
• 1221235-52-4 (R)-tert-butyl 6-((2-(tert-butoxycarbonyl(2-(3-(N-(tert-butoxycarbonyl)methylsulfonamide)phenyl)-2-triethylsilyloxy)ethyl)amino)ethoxy)-3-cyclopropylindazole-1-carboxylate 
• 1221235-59-1 (R)-tert-butyl 6-(2-(tert-butoxycarbonyl(2-(3-(N-(tert-butoxycarbonyl)methylsulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-3-cyclobutylindazole-1-carboxylate 
• 1221178-63-7 tert-butyl 6-((tert-butyldiphenylsilyl)oxy)-3-ethyl-1H-indazole-1-carboxylate 
• 1221178-62-6 6-((tert-butyldiphenyl-silyl)oxy)-3-ethyl-1H-indazole 
• 1221178-60-4 1-benzyl-3-ethyl-1H-indazol-6-ol 
• 1221178-56-8 tert-butyl 6-((tert-butyldiphenylsilyl)oxy)-3-isopropyl-1H-indazole-1-carboxylate 
• 1221178-55-7 6-((tert-butyldiphenylsilyl)oxy)-3-isopropyl-1H-indazole 

Relevant academic research and scientific papers

AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects

Novel indazole derivatives were prepared and evaluated for their biological activity and cardiovascular safety profile as human β3-adrenergic receptor (AR) agonists. Although the initial hit compound 5 exhibited significant β3-AR agonistic activity (EC50 = 21 nM), it also exhibited agonistic activity at the α1A-AR (EC50 = 219 nM, selectivity: α1A/β3 = 10-fold). The major metabolite of 5, which was an oxidative product at the indazole 3-methyl moiety, gave a clue to a strategy for improvement of the selectivity for β3-AR agonistic activity versus α1A-AR agonistic activity. Thus, modification of the 3-substituent of the indazole moiety effectively improved the selectivity to develop compound 11 with potent β3-AR agonistic activity (EC50 = 13 nM) and high selectivity (α1A/β3 = >769-fold). Compound 11 was also inactive toward β1 and β2-ARs and showed dose dependent β3-AR mediated relaxation of marmoset urinary bladder smooth muscle, while it did not obviously affect heart rate or blood pressure (iv, 3 mg/kg) in anesthetized rats.

INDAZOLE ANALOGUE

[Objective] To provide a drug that selectively stimulates the β3-adrenergic receptors, particularly a drug capable of preferentially stimulating the β3-adrenergic receptors over the α1-adrenergic receptors. This drug can be used in the treatment and prevention of diabetes, obesity, hyperlipidemia, depression, cholelithiasis, diseases caused by biliary hyperkinesia, diseases caused by hyperfunction of the gastrointestinal tract, interstitial cystitis, overactive bladder or urinary incontinence, diseases associated with decreased lacrimation, and the like. [Solution] Indazole analogs represented by the general formula (I) or a salt thereof. Drugs that contains these indazole analogs or a salt thereof as the active ingredient.

INDAZOLE DERIVATIVES

Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc.

INDAZOLE COMPOUNDS

Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.